Importance of Long-Term Safety Data in Plaque Psoriasis Treatment
Lakshi Aldredge, MSN, ANP-BC, comments on the implications of long-term safety data in patients who may not have responded to initial treatment of plaque psoriasis.
Systemic Treatment Options in Plaque Psoriasis
Laura Bush, DMSc, PA-C, provides an overview of systemic treatment options for patients with plaque psoriasis, highlighting the follow-up process once treatment has been implemented.
CASE 1 Presentation: 60-year-old African American Woman With GPP
August 17th 2023Erin Boh, MD, presents the case of a 60-year-old African American woman with generalized pustular psoriasis (GPP) covering her medical history, initial presentation, potential disease trigger, highlighting important comorbidities of concern and their impact on treatment selection.
Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study
August 16th 2023Christopher Bunick, MD, PhD, introduces the objectives and design of a study comparing the safety of Janus Kinase (JAK) inhibitors and systemic immunosuppressants in the treatment of atopic dermatitis (AD).
Escalating Treatment From Topical to Systemic in Plaque Psoriasis
Jennifer Conner, MPAS, PA-C, and Lakshi Aldredge, MSN, ANP-BC, comment on approaches to escalating treatment of plaque psoriasis from topical therapy to systemic therapy and initiating that conversation with the patient.
Patient Case #1: 50-Year-Old Female With Plaque Psoriasis
Experts in dermatology review a case of a patient with plaque psoriasis concentrated on her hands and discuss taking the patient’s preferences into consideration when selecting treatment.
Metrics to Determine Disease Clearance in Plaque Psoriasis
Laura Bush, DMSc, PA-C, and Terry Faleye, MPAS, PA-C, discuss metrics to determine clearance in plaque psoriasis and how the provider’s expectations may be different from the patient’s expectations.
Importance of Quick Response to Treatment for Patients With Plaque Psoriasis
Lakshi Aldredge, MSN, ANP-BC, discusses how speed of treatment response guides treatment selection for the patient, taking patient preference into consideration. Jennifer Conner, MPAS, PA-C, comments on treatment failure in plaque psoriasis.